Annals of Internal Medicine tip sheet for 27 Nov. 2012

November 26, 2012

1. Task Force Reviews Evidence to Update Hepatitis C Screening Recommendations for Asymptomatic Adults

In 2004, the United States Preventive Services Task Force recommended against routine screening for hepatitis C virus (HCV) infection in asymptomatic adults who are not at increased risk for infection. At the time, the Task Force also found insufficient evidence to recommend for or against routine HCV screening for adults at high risk for infection. Since then, other groups have recommended screening higher-risk patients, including a recommendation by the Centers for Disease Control and Prevention (CDC) to screen all persons born between 1945 and 1965. To inform an update to the 2004 Task Force recommendations, researchers studied published evidence focusing on research gaps identified in the previous review. The researchers sought to determine if screening for HCV infection in asymptomatic adults at low risk for infection would reduce mortality and morbidity due to HCV infection, affect quality of life, or reduce incidence of HCV infection. They also assessed the benefits, harms, and effectiveness of different screening methods. The researchers found no direct evidence that screening for HCV improves clinical outcomes, but the data suggest that targeted screening misses up to two-thirds of infected patients. Screening tests appear to be accurate for identifying HCV-infected patients with minimal risk of harm. Data on antiviral treatments were evaluated in a separate report and will be included in the recommendation statement. The draft recommendation will be posted to on November 27.

Note: For a PDF, please email or text Angela Collom. To speak with a member of the Task Force, please contact Ana Fullmer at or 202-350-6668.

2. Task Force Reviews Evidence on Antiviral Treatments to Inform Update of its Hepatitis C Recommendations

There are a number of treatments approved to treat chronic hepatitis C virus (HCV) infection. Researchers reviewed randomized trials of antiviral treatments and cohort studies examining the associations between sustained virologic response (SVR) after therapy with clinical outcomes to determine the benefits and harms of antiviral regimens in patients new to treatment (SVR rates are the primary outcome measure to evaluate comparative effectiveness). For patients new to treatment, dual therapy with pegylated interferon alfa-2b is associated with a lower likelihood of SVR than dual therapy with pegylated interferon alfa-2a, but pegylated interferon alfa-2b was associated with a lower incidence of adverse events. For genotype 2 or 3 infection, longer durations of treatment with standard-dose pegylated interferon as part of dual therapy are more effective than shorter regimens or lower doses. For genotype 1 infection, adding boceprevir or telaprevir to treatment (triple therapy) raised SVR to similar rates as dual therapy for genotype 2 or 3 infection. However, triple therapy is associated with a greater risk of adverse events. The researchers found no published evidence on long-term effectiveness of treatment on clinical outcomes.

Note: For a PDF, please email or text Angela Collom. To speak with a member of the Task Force, please contact Ana Fullmer at or 202-350-6668.

3. No Interventions Proven to Reduce Mother-to-child Transmission of Hepatitis C

Researchers have found no clear proof that any intervention reduces the risk for mother-to-child transmission of hepatitis C virus (HCV) infection. More than 40,000 children are born to HCV-positive women each year. Up to 10 percent of those children are HCV-positive due to maternal transmission. Researchers reviewed published evidence on mode of delivery, labor management strategies, and breastfeeding practices to determine their effect on risk of mother-to-infant transmission of HCV. The researchers found no clear evidence that any of the interventions reduce the risk of transmission. There was limited evidence that prolonged rupture of membranes could increase risk of mother-to-child transmission, suggesting that physicians should avoid prolonged rupture of membranes in women with HCV infection. The researchers found that avoidance of breastfeeding is not warranted to reduce risk of vertical transmission.

Note: For a PDF, please email or text Angela Collom. For an interview with Dr. Roger Chou, please email him directly at

American College of Physicians

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to